Market OpportunitySubstantial market opportunity within reach, with Rhythm estimating thousands of potential patients across the U.S., Japan, and the E.U.
Product EfficacyThe doc was highly encouraged by IMCIVREE's Ph3 efficacy in HO, with an expected high adoption rate.
Regulatory ProgressAn in-person pre-filing meeting with the FDA was recently held, which is encouraging against the backdrop of understaffing concerns.